Cadaverine Tartrate

Cadaverine Tartrate

SCHEMBL9936743

CC(=O)NCc1ccc(-c2ccc(C(C)C)cc2)cc1.O=C(O)C(O)C(O)C(=O)O

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 known ✓ P07550 1/20 0.43
ADRB1 known ✓ P08588 1/20 0.43
ADRB3 known ✓ P13945 1/20 0.43
ADAMTS4 O75173 1/20 0.53
MMP13 P45452 1/20 0.53
RAB9A P51151 5/20 0.52
KMT2A Q03164 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 2/20 0.52
ALDH1A1 P00352 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 2/20 0.47
GAA P10253 1/20 0.47
NPC1 O15118 3/20 0.46
RORC P51449 1/20 0.46
BACE1 P56817 1/20 0.45
HDAC1 Q13547 3/20 0.45
HDAC3 O15379 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC8 Q9BY41 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cadaverine Tartrate SCHEMBL9937385 0.88 KMT2A (0.53) ADAMTS4MMP13RAB9AKMT2ASMN1; SMN2
SCHEMBL13104785 0.86 RAB9A (0.61) RAB9AKMT2ASMN1; SMN2MEN1ALDH1A1
Cadaverine Tartrate SCHEMBL9938634 0.85 KMT2A (0.53) ADAMTS4MMP13RAB9AKMT2ASMN1; SMN2
Cadaverine Tartrate SCHEMBL9938548 0.85 KMT2A (0.55) ADAMTS4MMP13RAB9AKMT2ASMN1; SMN2
Cadaverine Tartrate SCHEMBL3634786 0.81 PPARA (0.51) ADAMTS4MMP13KMT2AHDAC1HDAC3
Cadaverine Tartrate SCHEMBL3633165 0.81 ADAMTS4 (0.48) ADAMTS4MMP13RAB9AKMT2ASMN1; SMN2
SCHEMBL5988669 0.78 KMT2A (0.58) ADAMTS4MMP13RAB9AKMT2ASMN1; SMN2
SCHEMBL5801663 0.76 KMT2A (0.65) ADAMTS4MMP13RAB9AKMT2ASMN1; SMN2
SCHEMBL3556571 0.76 ALDH1A1 (0.62) RAB9AKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL26161772 0.75 KMT2A (0.54) ADAMTS4MMP13RAB9AKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651403-A2 USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES Glaxo Group Limited (GB) 2013-10-23 EP disclosed
WO-2012080497-A2 METHODS OF TREATMENT AND PREVENTION OF EYE DISEASES GLAXO GROUP LIMITED (GB) 2012-06-21 WO disclosed